ストックスクリーナーアプリを入手
4.53
2.16%
-0.10
アフターアワーズ：
4.53
前日終値:
$4.63
開ける：
$4.64
24時間の取引高:
319.37K
Relative Volume:
1.15
時価総額：
$363.33M
収益：
$351.37M
当期純損益:
$-169.52M
株価収益率:
-2.1331
EPS:
-2.1237
ネットキャッシュフロー:
$-147.86M
1週間 パフォーマンス:
-12.12%
1か月 パフォーマンス:
-13.38%
6か月 パフォーマンス:
-22.96%
1年 パフォーマンス:
+43.81%
1日の値動き範囲:
$4.48
$4.805
1週間の範囲:
$4.48
$5.20
52週間の値動き範囲:
$2.87
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Compare AVIR vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
4.53 | 363.33M | 351.37M | -169.52M | -147.86M | -2.1237 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-13 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-10-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 開始されました | Evercore ISI | Outperform |
| 2020-11-24 | 開始されました | JP Morgan | Overweight |
| 2020-11-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-24 | 開始されました | William Blair | Outperform |
すべてを表示
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
Atrium Therapeutics Announces $50 Million Private Placement - Investing News Network
A stake in Atea Pharmaceuticals (AVIR) is no longer held to influence control. - Stock Titan
Atea Pharmaceuticals (AVIR) Climbs 2.33% to $5.27, Testing Key ResistanceSector Neutral Pair - careplusvn.com
AVIR: Atea Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - Yahoo Finance
Atea Pharmaceuticals Eyes 2028 Launch After Strong Phase 3 - TipRanks
Atea Pharmaceuticals (AVIR) Short Interest & Short Float | Updated Aug 2026 $AVIR - MarketBeat
Atea (AVIR) Latest Quarter: Reported EPS Tops Expectations for the Current Session; Trading Move: Shares Move 1.31% Up in the Current UpdateEarnings Call Highlights - vinanet.vn
Atea (AVIR) Session: Ends Higher by 1.31% at $5.43 in Latest Trading; Price Setup: Traders Can Monitor the $5.16-$5.70 Range for the Current SessionDividend Arbitrage - vinanet.vn
Vanguard Morningstar Total Stock Market ETF Holdings - Quiver Quantitative
Morgan Stanley Adjusts PT on Atea Pharmaceuticals to $7 From $6, Maintains Equalweight Rating - marketscreener.com
Atea Pharmaceuticals (AVIR.US) will release its earnings report after market close on August 12. - Moomoo
AVIR Holds Steady Near $5.06 as Atea Pharmaceuticals Tests Key Technical LevelsIV Crush Alert - dars.gov.et
AVIR Holds Steady Near $5.06 as Atea Pharmaceuticals Tests Key Technical LevelsNew Highs New Lows - dars.gov.et
Atea Pharmaceuticals, Inc. (AVIR) stock price, news, quote and history - Yahoo Finance UK
Atea Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Atea Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AVIR) 2026-08-12 - Seeking Alpha
Atea Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals Q2 Earnings Call Highlights - NewsBreak: Local News & Alerts
Atea Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Atea Pharmaceuticals Reports Q2 2026 Financials and Clinical Progress in Form 10-Q Filing - Kalkine Media
Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Earnings call transcript: Atea beats Q2 2026 EPS view but shares fall after hours - Investing.com
ATEA PHARMACEUTICALS ($AVIR) Releases Q2 2026 Earnings - Quiver Quantitative
Atea Pharmaceuticals (NASDAQ: AVIR) advances HCV Phase 3 as losses widen - Stock Titan
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a shareEarnings Preview - TradingView
AVIR Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Up 5.2%Profit Cycle Analysis - vinanet.vn
Atea Pharmaceuticals Leads Our Trio Of Promising Penny Stocks - webull.com
Arrowstreet Capital Limited Partnership Takes Position in Atea Pharmaceuticals, Inc. $AVIR - MarketBeat
Atea Pharmaceuticals, Inc. (AVIR) stock price, news, quote and history - Yahoo Finance Singapore
Atea Pharmaceuticals Leads Our Trio Of Promising Penny Stocks - simplywall.st
Atea's Aug. 12 webcast will include a business update - Stock Titan
Atea Pharmaceuticals to Host Second Quarter 2026 Financial - GlobeNewswire
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Atea Pharmaceuticals (AVIR) Projected to Post Earnings on Thursday - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Atea’s hep C pill looks solid in phase III head-to-head HCV study - BioWorld News
Atea Touts Drug Interaction Profile, Shorter Treatment In Taking On Hepatitis C Giants - insights.citeline.com
Atea posts late-stage trial win for hepatitis C drug (AVIR) - Seeking Alpha
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial - Benzinga
Atea Pharmaceuticals Reports Positive Topline Results From C-BEYOND Phase 3 Trial Evaluating Bemnifosbuvir/Ruzasvir For Hepatitis C Virus - marketscreener.com
Atea’s hepatitis C drug meets primary endpoint in phase 3 trial - Investing.com Canada
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus - GlobeNewswire
Atea’s hepatitis C drug meets primary endpoint in phase 3 trial - investing.com
Atea Pharmaceuticals Inc (AVIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atea Pharmaceuticals Inc (AVIR) 財務データ
収益
当期純利益
現金流量
EPS
Atea Pharmaceuticals Inc (AVIR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
536,097 |
| DUNCAN BARBARA GAYLE | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
92,350 |
| Polsky Bruce | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
124,806 |
| Murphy Polly A. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
121,745 |
| Adams Jerome M. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
92,350 |
| Corcoran Andrea | See Remarks |
Mar 11 '26 |
Option Exercise |
1.24 |
60,000 |
74,400 |
823,576 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Feb 03 '26 |
Option Exercise |
1.24 |
300,000 |
372,000 |
767,830 |
1.35%
大文字化:
|
ボリューム (24 時間):